OncoTherapy Science, Inc.
November 30, 2018
Announcement of a commissioned basic contract between OTS’s subsidiary company andCosmo Bio Co., Ltd. for peptide synthesis
OncoTherapy Science, Inc. (OTS) hereby announces that, its subsidiary company, Cancer
Precision Medicine, Inc. (CPM) concluded a commissioned basic contract with Cosmo Bio Co.,
Ltd. (CB) for the peptide synthesis in cancer immunotherapy.
This contract is for that, based on CPM's neoantigen analysis (*1) results, CB synthesizes anddelivers the commissioned peptides to CPM. CPM has concluded a collaborative research
agreement with Cancer Precision Medicine Center (director: Dr. Yusuke Nakamura) at theJapanese Foundation for Cancer Research, and has provided cancer-related genetic analysis
services such as liquid biopsy (*2) or neoantigen analysis to medical institutions and research
institutes. On the conclusion of this contract, CPM will request entrusted peptide synthesis toCB in order to shorten the period of peptide synthesis for cancer immunotherapy, and CPM
will provide a package service which can include neoantigen analysis as well as synthesizedpeptides to the medical institutions and research institutes.
Cancer immunotherapy is getting more attentions as a revolutionary cancer treatment via
activation of our body’s immune system. Neoantigen is a cancer-specific antigen derived froma somatic mutation (*3) in cancer cell and considered as an ideal target for cancer
immunotherapy. Neoantigen prediction (*4) is regarded as a very important step to develop
effective cancer therapeutic vaccines, as an individualized cancer immunotherapy.

Cosmo Bio Co., Ltd
Life science research biotools (reagents, kits, instruments, diagnostics, and software):import, export, manufacture, marketing, sales and customer support.
https://www.cosmobio.com/index.php(*1) neoantigen analysis
It is to analyze a cancer-specific antigen (neoantigen) that is derived from a somatic mutation
in a cancer cell and presented as a target of immune cell.
(*2) liquid biopsy
Cancer is a genetic disease with accumulation of genetic alterations. Recent advances in thenext-generation DNA sequencing technologies have enabled to detect the presence of cancer
in patient, by analyzing liquid specimens like blood and urine. This kind of approach is called
as “liquid biopsy” which can detect mutated ctDNA (circulating tumor DNA) with very highsensitivity. One of useful clinical applications of the liquid biopsy is very early detection oftumor recurrence, which may detect even earlier than tumor imaging examination like CT
1

(Computed Tomography). Moreover, liquid biopsy is a non-invasive and safe method thancollection of tumor tissue, and can be performed repeatedly.
(*3) somatic mutation
There are two types of genetic mutations, one is inherited mutation from parents and theother is acquired mutation occurring after birth, which is also called as somatic mutation. The
former mutation will be present in all cells of the body. On the other hand, the somatic
mutation is an acquired mutation, and will be present only in certain cells and their daughter
cells which have continuously proliferated.
(*4) neoantigen prediction
By use of computer algorithms, it is to predict “neoantigen peptides” which contain somaticgene mutations, expressed in cancer cells, and can strongly bind to patient's HLA molecules.
In the immune system, neoantigen peptides mark on cancer cells and induce very strong
cancer cell-specific immune responses.

2